Rome, 21 Sept. (Adnkronos Health) – Bacterial lysates, particularly Lantigen B, could play a role in reducing Sars-CoV-2 infections. An in vitro study shows that the pharyngeal mucosal cells, treated with an amount of Lantigen B * equivalent to the normal dosage required for taking the drug, reduce the expression of the Ace2 receptors which act as gateways of the virus on the cell surface . These are the results of the Italian study – available in a pre-print version and awaiting publication in an international peer-reviewed journal – coordinated by Giovanni Melioli, former head of the experimental medicine department at the Giannina Gaslini Institute and professor of laboratory management at the High School of Specialization of Clinical Pathology at the University of Genoa.
Bacterial lysates – explains a note – are old allies of the lungs. Developed in the 60s of the last century, they are a category of drugs that contain inactivated parts of bacteria, allowing the immune system to prepare in time to react to infections. Numerous studies in the last 50 years have scientifically proven that lysates stimulate the production of antibodies, reduce frequent respiratory tract infections and improve mucosal health, proving to be beneficial for both the elderly and children, categories particularly sensitive to seasonal ills. .
“We started – says Melioli – from an important US study conducted by a brilliant Italian scientist, Donata Vercelli who, using the important means made available to university research in the United States, demonstrated how a lysate similar to Lantigen B reduced both expression of Ace2 – the receptor that welcomes the Spike protein of Sars-CoV-2 – is, consequently, the possibility of infection of Covid-19 on monoclonal cells in the laboratory “. Based on the results of the American one,” we built a study – continues Melioli – that would test the results obtained by applying the research to cells of the pharyngeal mucosa taken with a simple swab from 15 volunteers. The cells remained in culture for 24 hours with 1-2mmgg of Lantigen B and then analyzed ” .
Two important things discovered by Italian researchers. “The first – explains the professor – is that four fifths of the cells drastically reduced the expression of the Ace2 receptor and that this result occurred in living cells of the body, the same ones that are the target of Sars-CoV-2 during the infection; the second is that the dosage at which this effect is obtained is the same as for the oral administration of Lantigen B “.
In light of these results, the group is “launching a new study – specifies Melioli – in order to demonstrate that the effect recorded in vitro on the cells taken from the pharynx also occurs in situ, ie in the larynx itself after taking Lantigen B by mouth. However, I believe that, given the simplicity of the model and the clarity of the results, the in vitro study will be confirmed by the in vivo one “.
The Italian research highlights one more strategy against Covid. “There are, at the moment – says the professor – three ways to protect yourself from Covid-19: not to get infected; the vaccine; antiviral drugs. I am confident that these new lines of research have revealed the existence of a fourth defense: bacterial lysates that reduce the possibility of being infected. This new resource against Covid-19 is not an alternative to the vaccine – he warns -. The vaccine is proven to be the tool that greatly reduces systemic effects (such as interstitial pneumonia) and more severe symptoms when we get infected. Lantigen B in turn promises to be the drug that helps us not to infect ourselves. An important result – also considering the other benefits of Lysate on the respiratory tract – for many of the categories at risk and, above all – concludes Melioli – for those who are not covered, for various reasons, by vaccination protection “.